illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Sinphar Pharmaceutical
Company logo

Sinphar Pharmaceutical | Sustainability Performance

https://www.sinphar.com.tw/en/
Linkedin

Produces and distributes pharmaceutical products and healthcare solutions. Offers research and development, manufacturing, and supply chain management for medicines and medical applications. Provides services across regulatory, clinical, and operational domains.

1977

Taiwan

501 - 1,000 employees

Pharmaceuticals

$100M - 500M in revenue

$10M - 25M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6846
Overall
#96
in Taiwan
#156
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusionsB-corp & CDP
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Scinopharm Taiwan

Taiwan, Hospital & Health Care, Pharmaceuticals


Company logo
TCI

Taiwan, Hospital & Health Care, Biotechnology


Company logo
Standard Chem & Pharm

Taiwan, Hospital & Health Care, Pharmaceuticals

Market cap

200.0B $, 2026▲17% YoY

Revenue

108.2M $, 2025▲6.6% YoY

R&D intensity

4.3% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

200.0B $, 2026▲17% YoY

Revenue

108.2M $, FY2025▲6.6% YoY

EBITDA

13.3M $, FY2025▼9.1% YoY

Operating margin

12% Industry: -24▲19.4% YoY

Revenue & EBITDA

$108.2MFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

10.8M 2024▲101.4% YoY

Capex

8.2M 2024▼17.2% YoY

Debt/equity ratio

0.4 Industry: 0▼NaN% YoY

R&D intensity

4.3%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

7.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.1

2023

0.1

▼ 1.3%

2024

0.1

▲ 53.9%

2025

3.5

2031

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

14%
Independent Directors

3 out of 21 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

CDP Scores


Climate Score

Not disclosed

Water Score

Not disclosed

A

A-

B

B-

C

C-

D

D-

Powered by illuminem and GIST impact

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email